185 related articles for article (PubMed ID: 35285018)
1. Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
Kregting LM; Sankatsing VDV; Heijnsdijk EAM; de Koning HJ; van Ravesteyn NT
Int J Cancer; 2022 Jul; 151(2):287-296. PubMed ID: 35285018
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Screening in Georgia: Choosing the Most Optimal and Cost-Effective Strategy.
Irzaldy A; Gvamichava R; Beruchashvili T; Sturua L; van Ravesteyn NT; de Koning HJ; Heijnsdijk EAM
Value Health Reg Issues; 2024 Jan; 39():66-73. PubMed ID: 37992568
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.
Geuzinge HA; Bakker MF; Heijnsdijk EAM; van Ravesteyn NT; Veldhuis WB; Pijnappel RM; de Lange SV; Emaus MJ; Mann RM; Monninkhof EM; de Koekkoek-Doll PK; van Gils CH; de Koning HJ;
J Natl Cancer Inst; 2021 Nov; 113(11):1476-1483. PubMed ID: 34585249
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.
Sankatsing VD; Heijnsdijk EA; van Luijt PA; van Ravesteyn NT; Fracheboud J; de Koning HJ
Int J Cancer; 2015 Oct; 137(8):1990-9. PubMed ID: 25895135
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study.
Chootipongchaivat S; Wong XY; Ten Haaf K; Hartman M; Tan KB; van Ravesteyn NT; Wee HL
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):653-660. PubMed ID: 33531436
[TBL] [Abstract][Full Text] [Related]
6. Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening.
Davidović M; Zielonke N; Lansdorp-Vogelaar I; Segnan N; de Koning HJ; Heijnsdijk EA
Value Health; 2021 Mar; 24(3):353-360. PubMed ID: 33641769
[TBL] [Abstract][Full Text] [Related]
7. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer : A Cost-Effectiveness Analysis.
Shih YT; Dong W; Xu Y; Etzioni R; Shen Y
Ann Intern Med; 2021 May; 174(5):602-612. PubMed ID: 33556275
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification in breast cancer screening: Cost-effectiveness and harm-benefit ratios for low-risk and high-risk women.
Sankatsing VDV; van Ravesteyn NT; Heijnsdijk EAM; Broeders MJM; de Koning HJ
Int J Cancer; 2020 Dec; 147(11):3059-3067. PubMed ID: 32484237
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
Tina Shih YC; Dong W; Xu Y; Shen Y
Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis.
Sankatsing VDV; Juraniec K; Grimm SE; Joore MA; Pijnappel RM; de Koning HJ; van Ravesteyn NT
Radiology; 2020 Oct; 297(1):40-48. PubMed ID: 32749212
[TBL] [Abstract][Full Text] [Related]
12. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
13. Total cost-effectiveness of mammography screening strategies.
Mittmann N; Stout NK; Lee P; Tosteson AN; Trentham-Dietz A; Alagoz O; Yaffe MJ
Health Rep; 2015 Dec; 26(12):16-25. PubMed ID: 26676235
[TBL] [Abstract][Full Text] [Related]
14. Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
Kregting LM; Vrancken Peeters NJMC; Clarijs ME; Koppert LB; Korfage IJ; van Ravesteyn NT
Int J Cancer; 2024 Jul; 155(1):117-127. PubMed ID: 38478916
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness evaluation of risk-based breast cancer screening in Urban Hebei Province.
Shi J; Guan Y; Liang D; Li D; He Y; Liu Y
Sci Rep; 2023 Feb; 13(1):3370. PubMed ID: 36849794
[TBL] [Abstract][Full Text] [Related]
16. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
Mital S; Nguyen HV
BMC Cancer; 2022 May; 22(1):501. PubMed ID: 35524200
[TBL] [Abstract][Full Text] [Related]
18. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study.
Huang HL; Leung CY; Saito E; Katanoda K; Hur C; Kong CY; Nomura S; Shibuya K
BMC Med; 2020 Sep; 18(1):257. PubMed ID: 32921305
[TBL] [Abstract][Full Text] [Related]
19. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.
Schousboe JT; Kerlikowske K; Loh A; Cummings SR
Ann Intern Med; 2011 Jul; 155(1):10-20. PubMed ID: 21727289
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
